On April 24, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Presentation:

Date and Time: Monday, April 27, 2026 at 8:00am ET

Toll Free: 1-877-407-9716

International: 1-201-493-6779

Conference ID: 13760371

Webcast Presentation: View Source;tp_key=efc315f5a6

A replay of the webcast and accompanying presentation will be available, for 90 days, following the event on the "Events" page under the Investors section of the Company’s website.

(Press release, Compass Therapeutics, APR 24, 2026, View Source [SID1234664762])

On April 24, 2026 Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, reported that it will provide several corporate updates in May 2026. Webcasts of these events, unless noted as press release only, will be posted on the Company’s website at www.perspectivetherapeutics.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Analyst Event on Perspective’s Strategy, Enabling Technology, and Pipeline
Additional details are available here.
Date: May 4, 2026
Time: 8:30 a.m. ET

First Quarter 2026 Financial Results – Press Release Only
The press release will be available on the newsroom section of the Company’s website at View Source
Date: May 11, 2026
Time: After the market closes

BofA Securities Health Care Conference – Fireside Chat
Date: May 13, 2026
Time: 2:20 p.m. PT / 5:20 p.m. ET

2026 RBC Capital Markets Global Healthcare Conference – Fireside Chat
Date: May 19, 2026
Time: 2:05 p.m. ET

(Press release, Perspective Therapeutics, APR 24, 2026, View Source [SID1234664763])

On April 24, 2026 Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, reported a corporate update on its partnership-driven strategy to advance its pipeline and enhance shareholder value.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the success of its joint venture with GMP Biotechnology, which contributed to a $249.0 million increase in the Company’s balance sheet for the most recent fiscal year through an independent third-party valuation, the Company is continuing to pursue additional partnerships that provide financial and commercialization support.

The Company believes this strategy enables the advancement of multiple drug candidates in parallel while maintaining a capital-efficient operating model, and represents an effective approach to unlocking the value of its robust intellectual property portfolio.

CEO Commentary

"Our joint venture strategy has demonstrated the ability to unlock value through strategic partnerships," said Dr. Vuong Trieu, Chairman and Chief Executive Officer of Oncotelic. "We believe this is the right strategy to unlock our robust portfolio of intellectual property at scale. We are currently in discussions with potential partners and are working to establish additional collaborations in the near term."

(Press release, Oncotelic, APR 24, 2026, View Source [SID1234664764])

On April 24, 2026 Novartis reported it has withdrawn a European Medical Agency type II variation application for Pluvicto to treat adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)1 pre-chemotherapy, following CHMP feedback. The CHMP indicated that they would not support the application based on the control arm used in the PSMAfore study. The withdrawal is not related to the quality, efficacy or safety of Pluvicto and does not impact ongoing clinical trials, approved indications or pending regulatory submissions inside or outside the EU.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Importantly, the PSMAfore study that supported the application, was the basis for successful approval of Pluvicto in pre-chemotherapy mCRPC patients in the United States, Japan, and China. The value of Pluvicto in this population is also reflected in evidence-based recommendations from leading professional guidelines, including ESMO (Free ESMO Whitepaper), EAU, ASCO (Free ASCO Whitepaper) and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)2.

We are disappointed by this outcome and remain committed to advancing treatment options for people with prostate cancer.

(Press release, Novartis, APR 24, 2026, View Source [SID1234664748])

On April 24, 2026 Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, reported that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 10,700 shares of the Company’s stock (the "Inducement Grant") to newly hired employees on April 22, 2026 (the "Grant Date"), in connection with the commencement of employment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the "Plan") as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

(Press release, Aligos Therapeutics, APR 24, 2026, View Source [SID1234664750])